These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24731676)

  • 1. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
    Bloomgarden ZT
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
    [No Abstract]   [Full Text] [Related]  

  • 2. Longacting exenatide in diabetes: DURATION-3.
    Misra A; Joshi S
    Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
    Nauck MA; Meier JJ
    Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
    [No Abstract]   [Full Text] [Related]  

  • 4. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 6. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
    Baruah MP; Kalra S
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):129-35. PubMed ID: 22435393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 10. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
    Rosenstock J; Shenouda SK; Bergenstal RM; Buse JB; Glass LC; Heilmann CR; Kwan AY; MacConell LA; Hoogwerf BJ
    Diabetes Care; 2012 May; 35(5):955-8. PubMed ID: 22432107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 15. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
    Porcellati F; Lucidi P; Bolli GB; Fanelli CG
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diabetologist/cardiologist debate: a meeting of the minds.
    Mohamed F; Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):115-7. PubMed ID: 22447480
    [No Abstract]   [Full Text] [Related]  

  • 17. The rationale for combining GLP-1 receptor agonists with basal insulin.
    Cohen ND; Audehm R; Pretorius E; Kaye J; Chapman LH; Colagiuri S
    Med J Aust; 2013 Aug; 199(4):246-9. PubMed ID: 23984780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
    Gurkan E; Tarkun I; Sahin T; Cetinarslan B; Canturk Z
    Diabetes Res Clin Pract; 2014 Dec; 106(3):567-75. PubMed ID: 25458329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
    Garg SK
    Diabetes Technol Ther; 2010 Jan; 12(1):11-24. PubMed ID: 20082581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.